Adeno-ceNOS gene therapy - Crucell

Drug Profile

Adeno-ceNOS gene therapy - Crucell

Latest Information Update: 26 Jan 2005

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Anti-ischaemics; Gene therapies
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis

Most Recent Events

  • 25 Jan 2005 Discontinued - Preclinical for Coronary artery restenosis in Belgium (unspecified route)
  • 25 Jun 1998 Preclinical development for Coronary artery restenosis in Belgium (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top